Browsing Tag
Vanda Pharmaceuticals
9 posts
Why AnaptysBio’s new CFO hire may matter more than a routine biotech appointment
AnaptysBio is no longer a classic biotech pipeline bet. Christopher Murphy’s CFO appointment tests whether ANAB can execute as a royalty vehicle.
Vanda Pharmaceuticals (VNDA) wins FDA’s first formal drug approval hearing in 40 years as Hetlioz jet lag battle enters new phase
FDA grants Vanda Pharmaceuticals a rare Part 12 public hearing on Hetlioz jet lag rejection, the first such drug approval hearing in 40 years. Read the full analysis.
Vanda Pharmaceuticals (NASDAQ: VNDA) wins long-awaited FDA approval for NEREUS, first new motion sickness drug in 40+ years
Find out how Vanda Pharmaceuticals’ FDA-approved NEREUS (tradipitant) is redefining motion sickness treatment after 40 years of stagnation. Read the full story now.
What Vanda’s December FDA deadlines could mean for motion sickness drug market leadership
Vanda Pharmaceuticals confirms FDA extension of tradipitant clinical hold review to December 5, while motion sickness NDA remains on track for December 30 decision.
How AnaptysBio’s 2026 spin-off plan could reshape its pipeline, royalty flows, and stock outlook
Discover how AnaptysBio (NASDAQ: ANAB) plans to split into two focused companies to unlock hidden value and reshape its investment story.
Vanda Pharmaceuticals’ VGT-1849A gets orphan drug designation for polycythemia vera treatment
Vanda Pharmaceuticals Inc. has achieved a critical regulatory milestone with the U.S. Food and Drug Administration (FDA) granting…
Cycle Pharmaceuticals proposes $466m acquisition of Vanda Pharmaceuticals
In a significant development within the pharmaceutical industry, UK-based Cycle Pharmaceuticals has offered to acquire Nasdaq-listed Vanda Pharmaceuticals…
Vanda Pharmaceuticals rejects Future Pak’s acquisition offer
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) has officially declined the latest acquisition proposal from Future Pak, LLC (FP), citing…
Vanda Pharmaceuticals gets FDA orphan drug status for VPO-227 in cholera
Vanda Pharmaceuticals has secured orphan drug designation for VPO-227 from the US Food and Drug Administration (FDA) for…